NeuroPace (NPCE) Profit After Tax Growth (1y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -12.28% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 99.26% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 4.70% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 125.69% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 89.28% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -27.13% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 51.30% |
| 10 | NeuroPace | 558.86 Mn | 504.88 Mn | 18.05 Mn | -1.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.52% |
| Dec 31, 2025 | 48.02% |
| Sep 30, 2025 | 35.88% |
| Jun 30, 2025 | -15.13% |
| Mar 31, 2025 | 26.17% |
| Dec 31, 2024 | 15.32% |
| Sep 30, 2024 | 24.87% |
| Jun 30, 2024 | 17.65% |
| Mar 31, 2024 | 13.98% |
| Dec 31, 2023 | 44.37% |
| Sep 30, 2023 | 38.42% |
| Jun 30, 2023 | 28.10% |
| Mar 31, 2023 | 9.48% |
| Dec 31, 2022 | -4.24% |
| Sep 30, 2022 | -45.80% |
| Jun 30, 2022 | -49.40% |
| Mar 31, 2022 | -30.09% |
| Dec 31, 2021 | -131.55% |
| Sep 30, 2021 | -95.90% |
| Jun 30, 2021 | 3.40% |
| Mar 31, 2021 | -30.69% |